Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin Versus Metformin in Polycystic Ovary Syndrome
NCT07811011Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Sep 2026
- Primary completion
- Mar 2027
01
Overview
Phase 3, randomised trial of vildagliptin in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Tanta University. Primary endpoints: Follicle-stimulating hormone at 3 months, Luteinizing hormone at 3 months and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
vildagliptin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT07811011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811011.